Novo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596
The planned pipeline addition remains subject to deal clearance, while future payments depend on milestones and sales.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Novo Nordisk (NVO) agreed to license Hengrui Pharma’s phase 1-ready oral candidate HRS-1596 in a deal worth up to $2.6 billion.
Novo will obtain exclusive rights to develop, manufacture and commercialise the GLP-1/GIP dual receptor agonist globally, excluding mainland China, Hong Kong, Macao and Taiwan. The agreement includes a $300 million upfront payment, milestone-contingent payments and royalties based on net sales in the licensed territory. Hengrui has approval in China to begin phase 1 trials for weight management and type 2 diabetes; once-weekly oral dosing remains a potential use. Closing is expected in the fourth quarter of 2026, subject to U.S. antitrust clearance and other customary conditions.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Exclusive rights would let Novo develop, manufacture and commercialise HRS-1596 across most global markets.
- Minor point. Forward-looking: it has not happened yet and may not happen.HRS-1596 is phase 1-ready, with potential for once-weekly oral dosing.
Negative
- Moderate pointU.S. antitrust clearance remains pending before the agreement can close.
- Minor point. Forward-looking: it has not happened yet and may not happen.$300 million upfront is payable under a deal worth up to $2.6 billion if applicable milestones are met.
- Minor point. Forward-looking: it has not happened yet and may not happen.Sales royalties would be payable to Hengrui on net sales in the licensed territory.
Key Figures
- Potential total deal value
- Up to $2.6 billion
- Contingent on applicable development, regulatory and commercial milestones
- Upfront payment
- $300 million
- License agreement
- Expected transaction closing
- Fourth quarter of 2026
- Subject to antitrust clearance and customary closing conditions
Key Terms
glp-1r medical
gipr medical
dual agonist medical
hart-scott-rodino antitrust improvements act regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
- HRS-1596 is a phase 1-ready GLP-1/GIP dual receptor agonist for once-weekly oral dosing
- Total potential deal value is up to 2.6 billion US dollars, including 300 million dollars upfront, as well as potential sales royalties
Bagsværd, Denmark, 29 September 2026 – Novo Nordisk today announced that it has entered into a license agreement with Hengrui Pharma (600276.SH; 01276.HK) for HRS-1596, a phase 1-ready glucagon-like peptide-1 receptor (GLP-1R) and gastric inhibitory polypeptide receptor (GIPR) dual agonist, with potential for once-weekly oral dosing.
Under the terms of the agreement, Novo will obtain exclusive rights to develop, manufacture and commercialise HRS-1596 globally, excluding mainland China, Hong Kong, Macao and Taiwan. The potential total value of the agreement is up to 2.6 billion US dollars contingent on the achievement of applicable development, regulatory and commercial milestones. This includes a 300 million dollars upfront payment. In addition, Hengrui Pharma is eligible to receive royalties based on net sales of HRS-1596 within the licensed territory.
"Novo has pioneered the field of oral peptides and as leaders, we continuously look to advance our broad and deep oral pipeline across obesity, diabetes and other cardiometabolic diseases through our strong internal capabilities and leading external innovation," said Martin Holst Lange, executive vice president, Research & Development and chief scientific officer at Novo. "Hengrui Pharma has a proven track record of discovering and advancing innovative therapies with the patients in the center, and we are excited to add HRS-1596 to our growing pipeline and to explore its potential to raise the bar for convenience in the field."
“We are committed to continuous innovation, bringing better treatments to patients. HRS-1596 reflects this commitment in metabolic diseases, with the potential to offer the convenience of once-weekly oral administration,” said Frank Jiang, MD, Ph.D., Executive Vice President and Chief Strategy Officer of Hengrui Pharma. “This collaboration brings together Hengrui’s innovation strengths and Novo’s global leadership in GLP-1 therapies and obesity care. Together, we aim to advance this innovative therapy for patients worldwide.”
HRS-1596 is designed to reduce weight and improve glycemic control through multiple mechanisms, including appetite suppression, stimulation of insulin secretion, and improved insulin sensitivity, supporting its potential use in obesity, type 2 diabetes, and other metabolic diseases. HRS-1596 has potential to be developed for once-weekly oral administration, which would substantially reduce dosing frequency and improve convenience compared with current offerings. Hengrui Pharma has received approval in China to initiate phase 1 clinical trials with HRS-1596 for weight management and type 2 diabetes.
The license agreement is subject to clearance under the U.S. Hart-Scott-Rodino Antitrust Improvements Act and the satisfaction of other customary closing conditions. The transaction is expected to close in the fourth quarter of 2026.
About Hengrui Pharma
Hengrui Pharma is an innovative, global pharmaceutical company dedicated to the research, development and commercialization of high-quality medicines to address unmet clinical needs. Its therapeutic areas of focus include oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. Driven by a patient-focused philosophy since its founding in 1970, Hengrui Pharma remains committed to advancing human health by striving to conquer diseases, improve health, and extend lives through the power of science and technology. For more information, visit us at Hengrui.com and follow us on LinkedIn.
About Novo
Novo is the global healthcare company that believes lasting health starts now. For over a century, we’ve combined leading scientific expertise with a deep understanding of people’s lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 67,000 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we’re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. For more information, visit novonordisk.com and follow us on Instagram, LinkedIn, TikTok, Facebook, X and YouTube.
Contacts for further information
| Novo Media: | |
| Ambre James-Brown +45 3079 9289 globalmedia@novonordisk.com | Liz Skrbkova (US) +1 609 917 0632 USMediaRelations@novonordisk.com |
| Novo Investors: | |
| Michael Novod +45 3075 6050 nvno@novonordisk.com | Sina Meyer +45 3079 6656 azey@novonordisk.com |
| Christoffer Togo Solgaard-Tullin +45 3079 1471 cftu@novonordisk.com | Max Ung +45 3077 6414 mxun@novonordisk.com |
| Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com | Mads Berner Bruun +45 3075 2936 mbbz@novonordisk.com |
| Frederik Taylor Pitter (US) +1 609 613 0568 fptr@novonordisk.com | Alex Bruce (US) +1 640 230 0276 axeu@novonordisk.com |
Attachment
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What rights would Novo Nordisk receive under the HRS-1596 license agreement?
Novo would receive exclusive rights to develop, manufacture and commercialise HRS-1596 globally, excluding mainland China, Hong Kong, Macao and Taiwan. The agreement remains subject to closing conditions.
How much could Novo Nordisk pay under the HRS-1596 agreement?
The agreement has a potential total value of up to $2.6 billion, including a $300 million upfront payment. The total depends on applicable development, regulatory and commercial milestones. Hengrui is also eligible for royalties based on net sales in the licensed territory.